Crinetics Pharmaceuticals (CRNX) Competitors $55.37 +0.74 (+1.35%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CRNX vs. TEVA, BGNE, MRNA, VTRS, SMMT, GMAB, RDY, SRPT, CTLT, and PCVXShould you be buying Crinetics Pharmaceuticals stock or one of its competitors? The main competitors of Crinetics Pharmaceuticals include Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Moderna (MRNA), Viatris (VTRS), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Catalent (CTLT), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry. Crinetics Pharmaceuticals vs. Teva Pharmaceutical Industries BeiGene Moderna Viatris Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Sarepta Therapeutics Catalent Vaxcyte Teva Pharmaceutical Industries (NYSE:TEVA) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk, community ranking and institutional ownership. Does the MarketBeat Community favor TEVA or CRNX? Teva Pharmaceutical Industries received 1170 more outperform votes than Crinetics Pharmaceuticals when rated by MarketBeat users. However, 69.20% of users gave Crinetics Pharmaceuticals an outperform vote while only 67.77% of users gave Teva Pharmaceutical Industries an outperform vote. CompanyUnderperformOutperformTeva Pharmaceutical IndustriesOutperform Votes132567.77% Underperform Votes63032.23% Crinetics PharmaceuticalsOutperform Votes15569.20% Underperform Votes6930.80% Is TEVA or CRNX more profitable? Crinetics Pharmaceuticals has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -5.73%. Teva Pharmaceutical Industries' return on equity of 42.92% beat Crinetics Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-5.73% 42.92% 7.25% Crinetics Pharmaceuticals N/A -36.12%-31.89% Which has more volatility and risk, TEVA or CRNX? Teva Pharmaceutical Industries has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Does the media favor TEVA or CRNX? In the previous week, Teva Pharmaceutical Industries had 5 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 17 mentions for Teva Pharmaceutical Industries and 12 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 0.93 beat Teva Pharmaceutical Industries' score of 0.76 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 10 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in TEVA or CRNX? 54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are owned by company insiders. Comparatively, 6.0% of Crinetics Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better earnings and valuation, TEVA or CRNX? Crinetics Pharmaceuticals has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$16.77B1.41-$559M-$0.85-24.56Crinetics Pharmaceuticals$1.04M4,942.16-$214.53M-$3.73-14.84 Do analysts recommend TEVA or CRNX? Teva Pharmaceutical Industries currently has a consensus price target of $19.67, indicating a potential downside of 5.81%. Crinetics Pharmaceuticals has a consensus price target of $70.82, indicating a potential upside of 27.90%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Crinetics Pharmaceuticals is more favorable than Teva Pharmaceutical Industries.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78Crinetics Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91 SummaryCrinetics Pharmaceuticals beats Teva Pharmaceutical Industries on 11 of the 18 factors compared between the two stocks. Ad Porter & CompanyA conspiracy Trump won’t unsealNew documentary reveals the lost wealth-building secret hidden deep within ancient religious texts from almost every civilization… an investment one expert says is “so perfect that only God could have created it.” Watch it now to discover how this asset that you’ve likely never considered before can produce returns so safe, secure, and endless it is nothing short of miraculous.This is the untold, true story of God’s Investment. Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRNX vs. The Competition Export to ExcelMetricCrinetics PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.13B$6.87B$5.18B$9.31BDividend YieldN/A3.06%4.78%4.06%P/E Ratio-14.8410.80127.8817.55Price / Sales4,942.16286.451,262.65139.48Price / CashN/A56.6541.1037.95Price / Book6.865.394.894.92Net Income-$214.53M$152.04M$119.61M$225.78M7 Day Performance-3.15%-5.54%14.55%-1.47%1 Month Performance1.19%0.33%17.43%5.36%1 Year Performance60.68%16.04%35.33%22.71% Crinetics Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRNXCrinetics Pharmaceuticals4.2142 of 5 stars$55.37+1.4%$70.82+27.9%+60.7%$5.13B$1.04M-14.84210Analyst ForecastShort Interest ↓Positive NewsTEVATeva Pharmaceutical Industries2.0247 of 5 stars$16.66+1.0%$19.67+18.0%+109.2%$18.87B$16.77B-19.7937,851Options VolumeNews CoverageGap UpBGNEBeiGene2.6509 of 5 stars$176.52-1.6%$253.69+43.7%-2.2%$17.20B$2.46B-21.7710,600MRNAModerna4.4064 of 5 stars$41.59-0.6%$79.50+91.2%-52.6%$16.00B$5.06B-7.195,600VTRSViatris1.4196 of 5 stars$12.71+0.6%$13.67+7.5%+22.6%$15.17B$15.05B-17.0738,000SMMTSummit Therapeutics3.4066 of 5 stars$18.71+4.9%$33.33+78.2%+625.4%$13.80B$700,000.00-63.68105GMABGenmab A/S4.2563 of 5 stars$20.14-0.1%$45.20+124.4%-35.1%$13.33B$19.84B19.582,204Short Interest ↓High Trading VolumeRDYDr. Reddy's Laboratories2.1274 of 5 stars$14.75+2.0%$17.00+15.3%+8.6%$12.31B$299.87B22.9527,048SRPTSarepta Therapeutics4.9058 of 5 stars$126.12+1.9%$178.71+41.7%+35.2%$12.05B$1.64B98.971,314Insider TradePositive NewsCTLTCatalent2.7772 of 5 stars$63.48+0.7%$63.40-0.1%+53.0%$11.52B$4.38B-27.9116,900High Trading VolumePCVXVaxcyte1.8076 of 5 stars$90.59+3.3%$147.50+62.8%+48.4%$11.29BN/A-19.07160 Related Companies and Tools Related Companies Teva Pharmaceutical Industries Competitors BeiGene Competitors Moderna Competitors Viatris Competitors Summit Therapeutics Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Sarepta Therapeutics Competitors Catalent Competitors Vaxcyte Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRNX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRNX Stock Alerts